Literature DB >> 10895132

Evidence-based management of cancer in the elderly.

L Balducci1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10895132     DOI: 10.1177/107327480000700412

Source DB:  PubMed          Journal:  Cancer Control        ISSN: 1073-2748            Impact factor:   3.302


× No keyword cloud information.
  4 in total

1.  Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986.

Authors:  Maria De Santis; Joaquim Bellmunt; Graham Mead; J Martijn Kerst; Michael Leahy; Pablo Maroto; Thierry Gil; Sandrine Marreaud; Gedske Daugaard; Iwona Skoneczna; Sandra Collette; Julie Lorent; Ronald de Wit; Richard Sylvester
Journal:  J Clin Oncol       Date:  2011-12-12       Impact factor: 44.544

2.  Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986.

Authors:  Maria De Santis; Joaquim Bellmunt; Graham Mead; J Martijn Kerst; Michael Leahy; Pablo Maroto; Iwona Skoneczna; Sandrine Marreaud; Ronald de Wit; Richard Sylvester
Journal:  J Clin Oncol       Date:  2009-09-28       Impact factor: 44.544

3.  Inhibiting bladder tumor growth with a cell penetrating R11 peptide derived from the p53 C-terminus.

Authors:  Tingting Zhang; Kaijie Wu; Chen Ding; Kangwei Sun; Zhenfeng Guan; Xinyang Wang; Jer-Tsong Hsieh; Dalin He; Jinhai Fan
Journal:  Oncotarget       Date:  2015-11-10

4.  Immunotherapy for urothelial carcinoma: current status and perspectives.

Authors:  Hiroshi Kitamura; Taiji Tsukamoto
Journal:  Cancers (Basel)       Date:  2011-07-29       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.